Imfinzi is approved in the USA for the treatment of lung cancer

Imfinzi is approved in the USA for the treatment of lung cancer

Tatiana Kublitskaya, Pharmaceutical Bulletin

American regulators have expanded the indications for the use of the immunotherapy drug Imfinzi from AstraZeneca / MedImmune: now it is indicated for the treatment of patients with a certain form of lung cancer, PharmaTimes reports.

The FDA authorizes the use of the drug for the treatment of inoperable grade III non-small cell lung cancer in patients without disease progression after chemoradiotherapy with platinum preparations.

Imfinzi (durvalumab), a human monoclonal antibody to PD-L1 (1–VM programmed death protein ligand), has already received accelerated approval for the treatment of certain patients with locally advanced or metastatic urothelial cancer.

The expansion of indications for use is based on data from the Phase III PACIFIC clinical trial, which demonstrated an improvement in the median progression-free survival in patients taking Imfinzi compared to the placebo group (16.8 months. compared to 5.6 months, respectively).

The possibility of approving the drug for a new indication is currently being considered by European regulators.

Portal "Eternal youth" http://vechnayamolodost.ru